[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334308-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334308-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advancing-precision-medicine-in-esophageal-squamous-cell-carcinoma-using-patient-derived-organoids-research-methods-and-clinical-validation","Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids - Research methods and clinical validation","","Patient-derived organoids (PDOs) are presented as a promising approach to reproduce key features of original tumors and enable drug testing for personalized therapy across diverse cancers. Evidence for applying PDOs in esophageal cancer remains limited. This study evaluates whether implementing PDOs in clinical practice can improve outcomes for patients with esophageal squamous cell carcinoma by establishing PDOs from fresh surgical biopsies, characterizing them histologically, testing drug sensitivity using a customized chemotherapy-based drug panel, and correlating sensitivity profiles with patients’ actual treatment responses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advancing-precision-medicine-in-esophageal-squamous-cell-carcinoma-using-patient-derived-organoids-research-methods-and-clinical-validation/334308/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advancing-precision-medicine-in-esophageal-squamous-cell-carcinoma-using-patient-derived-organoids-research-methods-and-clinical-validation/334308.png","ImageObject",300,407,{"name":42,"@type":43},"Theodora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were patient-derived organoids (PDOs) established for ESCC patients?","Question",{"text":63,"@type":64},"Fresh surgical biopsies from patients with esophageal cancer were used to establish PDOs, which were then characterized histologically.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What was done to evaluate drug sensitivity in the PDOs?",{"text":68,"@type":64},"A customized drug panel based on standard-of-care chemotherapy regimens was applied to the PDOs to generate drug sensitivity profiles.",{"name":70,"@type":61,"acceptedAnswer":71},"How did PDO drug sensitivity relate to patient clinical outcomes?",{"text":72,"@type":64},"The chemotherapy-sensitivity classification matched clinical responses, and the paclitaxel plus cisplatin (TP)-sensitive group showed significantly longer progression-free survival than resistant groups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334308,1790125958,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":4},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Shen et al. Journal of Translational Medicine (2024) 22:1168  \n[https://doi.org/10.1186/s12967-024-05967-1](https://doi.org/10.1186/s12967-024-05967-1)  \nJournal of Translational Medicine  \n RESEARCH Open Access  \nAdvancing precision medicine in esophageal   squamous cell carcinoma using patient-derived organoids  \nSuya Shen1, Bing Liu2, Wenyan Guan3, Ziyao Liu4, Yuqing Han1, Yingzhe Hu5, Yiqiang Chen4, Siyuan Liu4, Jian He6, Zhiwen Li3, Weifeng Tang7, Pengju Zhang8, Wei Ren9*, Yudong Qiu1*, Hongping Zheng8,10* and Jingjing Li4*  \nAbstract  \nBackground Patient-derived organoids (PDOs) represent a promising approach for replicating the characteristics of original tumors and facilitating drug testing for personalized treatments across diverse cancer types. However, clinical evidence regarding their application to esophageal cancer remains limited. This study aims to evaluate the efficacy of implementing PDOs in clinical practice to benefit patients with esophageal squamous cell carcinoma (ESCC) . Methods Fresh surgical biopsies were obtained from patients with esophageal cancer for the establishment of PDOs. These PDOs were subsequently characterized through histological analysis. A customized drug panel, based on standard-of-care chemotherapy regimens, was applied to the PDOs. The resulting drug sensitivity profiles were then correlated with the clinical responses observed in individual patients undergoing actual treatment.  \nResults A total of 34 PDOs were successfully established with a 61. 8% success rate. The classification method based on chemotherapy sensitivity closely corresponded to clinical responses. The paclitaxel plus cisplatin (TP)-sensitive group demonstrated significantly longer progression-free survival (PFS) compared to the resistant groups, Hazard ratio (HR), 5 . 12; 95% confidence intervals (CI 0 .58–44. 71; p \u003C 0. 05), thus illustrating the potential of this approach for guiding personalized treatment strategies.  \nConclusion Organoid biobanks were established across multiple institutes to facilitate PDOs-based functional precision medicine. The findings demonstrate that this framework offers robust predictive value in clinical settings, enhances precision therapeutics, and advances drug discovery for esophageal cancer.  \nKeywords Esophageal squamous cell carcinoma, Organoids, Chemotherapy, Precision medicine  \n*Correspondence:  \nWei Ren [renwei@njglyy.com](renwei@njglyy.com)[ ](renwei@njglyy.com)Yudong Qiu [yudongqiu510@nju.edu.cn](yudongqiu510@nju.edu.cn)[ ](yudongqiu510@nju.edu.cn)Hongping Zheng [80885626@qq.com](80885626@qq.com)[ ](80885626@qq.com)Jingjing Li[jijilee_82@163.com](jijilee_82@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nShen et al. Journal of Translational Medicine (2024) 22:1168 Page 2 of 16  \nGraphical Abstract  \nInt","cbCaibRQGG1i7dzd","https://ap.wps.com/l/cbCaibRQGG1i7dzd","pdf",3768536,16,"English","# Introduction\n## Precision medicine limitations in esophageal cancer\n# Methods\n## PDO establishment and characterization\n## Drug panel and sensitivity profiling\n## Correlating PDO responses with clinical outcomes\n# Results\n## PDO establishment rate and sensitivity-based classification\n## Progression-free survival associated with TP sensitivity\n# Conclusion","[{\"question\":\"How were patient-derived organoids (PDOs) established for ESCC patients?\",\"answer\":\"Fresh surgical biopsies from patients with esophageal cancer were used to establish PDOs, which were then characterized histologically.\"},{\"question\":\"What was done to evaluate drug sensitivity in the PDOs?\",\"answer\":\"A customized drug panel based on standard-of-care chemotherapy regimens was applied to the PDOs to generate drug sensitivity profiles.\"},{\"question\":\"How did PDO drug sensitivity relate to patient clinical outcomes?\",\"answer\":\"The chemotherapy-sensitivity classification matched clinical responses, and the paclitaxel plus cisplatin (TP)-sensitive group showed significantly longer progression-free survival than resistant groups.\"}]","Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids - Research methods and clinical validation | PDF",1790006223]